Epidemiology and Molecular Drug-Resistance Patterns of Tuberculosis in Non-Elderly Patients in Luoyang, China, 2019-2023.

Purpose: Existing data offer limited guidance on TB control strategies for the non-elderly population, hampering effective epidemic management. This study aimed to analyze TB transmission and molecular resistance profiles among non-elderly patients (<60 years) in Luoyang City.

Patients And Methods: From 2019-2023, 24,706 non-duplicate sputum samples from 10 TB-designated hospitals were tested for  (MTBC) via IS6110-targeted real-time PCR. MTBC-positive specimens underwent multicolor melting curve analysis (MMCA) to assess resistance to isoniazid (INH), rifampin (RFP), streptomycin (SM), and ethambutol (EMB). Age-stratified analyses were performed to compare drug-resistant TB (DR-TB) prevalence between elderly and non-elderly groups, with multivariate regression identifying resistance risk factors in non-elderly patients.

Results: Non-elderly individuals exhibited significantly higher TB (17.54% vs 15.26%) and DR-TB (26.82% vs 21.62%) rates than the elderly (all,  < 0.001). Among non-elderly patients, males, retreatment cases, main urban residents and smear-positive groups had significantly elevated MTBC detection rates. The predominant resistance patterns of multidrug-resistant tuberculosis (MDR-TB) and poly-resistant tuberculosis (PDR-TB) were MDR4 (INH + RFP + EMB + SM) and PDR2 (INH + SM), with detection rates of 5.52% (142) and 2.33% (60), respectively. MTBC positive rate peaked at 30-34 years (23.10%), while the resistance rate peaked at 35-39 years. After adjusting for the effects of smear results and diagnosis year, the multivariate regression analysis model indicated that male sex, retreatment, and the main urban area were high-risk factors for TB resistance in non-elderly cases.

Conclusion: The non-elderly population demonstrates a significantly higher burden of both TB detection and resistance, particularly among males, retreatment cases, and main urban patients. The emergence of complex drug resistance patterns, combined with a distinct trend of younger age at infection, highlights the critical need for targeted interventions tailored to specific epidemiological and resistance profiles of MTBC-infected populations.